Pregled bibliografske jedinice broj: 966184
Expression profiles of P53/P73 isoforms in human melanoma cell lines
Expression profiles of P53/P73 isoforms in human melanoma cell lines // Abstracts of the 25th Biennial Congress of the European Association for Cancer Research, in ESMO Open, Volume 3, Supplement 2 / Berns, Anton (ur.).
London : Delhi: European Society for Medical Oncology, 2018. str. A289-A289 doi:10.1136/esmoopen-2018-EACR25.681 (poster, međunarodna recenzija, sažetak, znanstveni)
CROSBI ID: 966184 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Expression profiles of P53/P73 isoforms in human
melanoma cell lines
Autori
Slade, Neda ; Hanžić, Nikolina ; Radić, Martina ; Ozretić, Petar ; Petrović, Lidija ; Jazvinšćak Jembrek, Maja
Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni
Izvornik
Abstracts of the 25th Biennial Congress of the European Association for Cancer Research, in ESMO Open, Volume 3, Supplement 2
/ Berns, Anton - London : Delhi : European Society for Medical Oncology, 2018, A289-A289
Skup
25th Biennial Congress of the European Association for Cancer Research (EACR25)
Mjesto i datum
Amsterdam, Nizozemska, 30.06.2018. - 03.07.2018
Vrsta sudjelovanja
Poster
Vrsta recenzije
Međunarodna recenzija
Ključne riječi
p53 protein ; metastatic melanoma ; BRAF inhibitors
Sažetak
TP53 is the most frequently mutated gene in human cancer. However, in metastatic melanoma mutations of TP53 occur infrequently and p53 fails to function as a tumour suppressor. The altered expression of p53 family members, including p53/p73 isoforms, as well as of the interactions among them could affect the normal function of p53. Furthermore, somatic BRAF mutations have been found in 37%–50% of all melanomas, of which almost 90% harbour the activating V600E mutation. Although the initial response to BRAF inhibitors is highly effective, the resistant clones frequently develop, and, in treated patients disease progression is observed within 6 to 8 months. To address this, a better understanding of the genetic basis of melanoma initiation and progression is needed.
Izvorni jezik
Engleski
Znanstvena područja
Temeljne medicinske znanosti
POVEZANOST RADA
Projekti:
IP-2013-11-1615 - Otkrivanje novih proteinskih interakcija kao podloga za nove pristupe liječenju melanoma čovjeka (ProNetMel) (Slade, Neda, HRZZ - 2013-11) ( CroRIS)
Ustanove:
Institut "Ruđer Bošković", Zagreb
Profili:
Maja Jazvinšćak Jembrek
(autor)
Martina Radić
(autor)
Nikolina Hanžić
(autor)
Neda Slade
(autor)
Petar Ozretić
(autor)
Citiraj ovu publikaciju:
Časopis indeksira:
- Web of Science Core Collection (WoSCC)
- Emerging Sources Citation Index (ESCI)